SAN DIEGO, CA — January 16, 2026 — Leads & Copy — Quantumzyme Corp. (OTC: QTZM), a biotechnology company focused on enzyme-driven green chemistry solutions, has signed a Memorandum of Understanding (MoU) with Predictive Research Inc., an artificial intelligence and data science company.
The agreement will allow both organizations to explore potential collaboration opportunities at the intersection of artificial intelligence, biocatalysis, and sustainable chemical innovation.
The MoU provides a framework for evaluating the application of artificial intelligence, machine learning, and data-driven methodologies to support research and development in enzyme engineering, green chemistry, and related pharmaceutical and industrial processes.
Quantumzyme specializes in biotransformation and computational enzyme engineering, with a focus on developing sustainable alternatives to conventional chemical processes. The company uses quantum mechanics-informed modeling, molecular simulation, and computational design tools through its QZyme Workbench™ platform to optimize enzyme activity, selectivity, and stability.
Quantumzyme’s research is directed toward applications across pharmaceuticals, specialty chemicals, fragrances, food ingredients, and textiles, where biocatalysts may offer pathways to reduced environmental impact and improved process efficiency.
Predictive Research has experience in generative artificial intelligence, natural language processing, machine learning, and advanced analytics, providing data-driven solutions across sectors such as healthcare, life sciences, finance, retail, telecommunications, and automotive.
The potential collaboration areas outlined in the MoU include evaluating AI-supported approaches to enzyme engineering and green chemistry research; assessing data-driven methodologies to inform sustainable biotransformation concepts; exploring AI-enabled insights derived from complex biological and chemical datasets; and facilitating structured knowledge sharing between scientific and data science teams.
Quantumzyme Corp. CEO Naveen Krishnarao Kulkarni said the MoU reflects the company’s interest in evaluating how AI and data-driven approaches may complement its computational enzyme engineering platform.
Predictive Research Inc. Chief Data Scientist Dr. Basavaraj S. Patil added that the MoU represents an opportunity to explore how generative AI and predictive analytics could be applied within biochemical and catalytic research environments. He said that combining technical perspectives will allow both organizations to assess new approaches to data-informed innovation in life sciences.
Naveen Kulkarni
Chief Executive Officer
Quantumzyme Corp.
Phone: +1 (858) 225-2902
Email: info@quantumzymecorp.com
Source: Quantumzyme Corp.
